Print Page      Close Window     

Press Release

Exelixis Announces January 12 Webcast of Presentation at the J.P. Morgan 29th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec 17, 2010 (BUSINESS WIRE) -- Exelixis, Inc. (NASDAQ:EXEL) announced today that Michael Morrissey, Ph.D., the company's president and chief executive officer, will present at the 29th annual J.P. Morgan Healthcare Conference at 10:30 a.m. EST / 7:30 a.m. PST on Wednesday, January 12, 2011 in San Francisco. Dr. Morrissey will discuss the company's development plans and priorities for XL184, future data presentations, corporate strategy and financial outlook, and will provide a general business update.

The event will be webcast and may be accessed in the Event Calendar page under Investors at

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo. For more information, please visit the company's web site at

SOURCE: Exelixis, Inc.

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President,
Investor Relations and
Corporate Communications